Firms across various sectors are showing interest in expanding their domestic operations to appease the president. Analysts ...

Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

President Trump wants to bring manufacturing back to the U.S. These companies say they're investing in domestic factories.

What a CEO makes can be staggering from the seat of a rank-and-file employee, whose pay is typically in the five-to-six digit ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level ...

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example at home1-4Phesgo ...

President Trump’s proposed 25% tariff on pharmaceutical imports, largely from Ireland, could raise U.S. drug costs by nearly ...

While pharma manufacturing deals in the US increased, large cuts to research and regulatory agencies increased concerns for ...

Merck & Co. will grow its U.S. manufacturing footprint with a $1 billion plant in Delaware, becoming the latest drugmaker to ...

Sir Pascal Soriot is usually steps ahead of the game, so always worth listening to. His latest red flag is that Europe is ...

Donald Ingber, MD, PhD; Miguel Forte, MD, PhD; Ali Pashazadeh, MRCS, MBA; and Adam Inche, PhD, MBA go behind the headlines to ...